Outcome

This study concludes that administering 1.5 ATA hyperbaric oxygen therapy (HBOT) over 40 sessions within 30 days can significantly improve the condition of military subjects suffering from chronic blast-induced mild to moderate traumatic brain injury (TBI) post-concussion syndrome (PCS) and post-traumatic stress disorder (PTSD).

Introduction

This study explores the potential of low-pressure hyperbaric oxygen therapy (HBOT) for military personnel with chronic blast-induced mild to moderate traumatic brain injury (TBI) post-concussion syndrome (PCS) and post-traumatic stress disorder (PTSD). Sixteen military subjects underwent 40 HBOT sessions at 1.5 ATA for 60 minutes each over 30 days. The results demonstrated significant improvements in symptoms cognitive performance and quality of life. Cognitive function enhancements were particularly notable with increases in full-scale IQ and better performance on various neuropsychological tests. Subjective reports indicated reduced mood and anxiety disturbances complementing objective improvements seen in neurological exams and SPECT brain imaging which showed improved cerebral blood flow. While some adverse events such as reversible middle ear barotrauma and transient symptom changes were reported the therapy was generally safe. This study suggests that 1.5 ATA HBOT is an effective and safe treatment for improving brain function and quality of life in military subjects with chronic blast-induced TBI PCS and PTSD.

Results

The study evaluated the effects of 1.5 ATA hyperbaric oxygen therapy (HBOT) on 16 military subjects with chronic blast-induced mild to moderate traumatic brain injury (TBI) post-concussion syndrome (PCS) and post-traumatic stress disorder (PTSD). Subjects underwent 40 HBOT sessions over a 30-day period.

The findings were significant and multifaceted:

1. Cognitive Function: Subjects exhibited substantial improvements in cognitive performance with a notable increase in full-scale IQ (an average gain of 14.8 points). Enhanced outcomes were observed in tests measuring delayed memory working memory and various neuropsychological functions including the Stroop Test TOVA Impulsivity and Grooved Pegboard performance.
2. Symptom Improvement: Participants reported marked amelioration in mood and anxiety levels along with reductions in impulsivity. These improvements translated into better overall quality of life as assessed by validated measures.
3. Neurological Outcomes: Clinical neurological examinations indicated significant positive changes reinforcing the subjective reports and cognitive test improvements.
4. SPECT Imaging Results: Single-Photon Emission Computed Tomography (SPECT) brain imaging demonstrated enhanced cerebral blood flow with notable improvements in both white and gray matter regions. These imaging results corroborated the clinical and cognitive findings indicating improved brain perfusion and function.
5. Adverse Events: The therapy was generally safe with adverse events being mostly minor and reversible. Reported issues included middle ear barotrauma transient symptom deterioration and reversible bronchospasm. One subject withdrew from the study due to these side effects.

Overall the study highlights the potential of 1.5 ATA HBOT to significantly enhance cognitive function alleviate symptoms and improve the quality of life in military subjects with chronic blast-induced TBI/PCS and PTSD. These findings advocate for HBOT as an effective therapeutic intervention demonstrating notable benefits in both subjective and objective measures of brain health and function.

Conclusion

In conclusion this study highlights the promising impact of low-pressure hyperbaric oxygen therapy (HBOT) at 1.5 ATA over 40 sessions within 30 days on military subjects with chronic blast-induced mild to moderate traumatic brain injury (TBI) post-concussion syndrome (PCS) and post-traumatic stress disorder (PTSD). Key findings indicate significant improvements in symptoms cognitive performance quality of life and cerebral blood flow as measured by SPECT imaging.

The observed enhancements in mood anxiety impulsivity memory and overall cognitive function suggest that HBOT could serve as a potent therapeutic option for these complex conditions. The treatment’s safety profile despite some manageable adverse events further underscores its viability.

These preliminary results set a compelling foundation for future research. Expanding this study to include larger and more diverse populations could provide more robust data and further establish HBOT’s therapeutic potential. Ultimately this research offers valuable insights that could revolutionize the management of TBI PCS and PTSD particularly in military settings.